Elastin stabilization of connective tissue
A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.
1. A method for stabilizing connective tissue in a living subject, the method comprising,
surgically accessing the connective tissue of a blood vessel, and
applying an effective amount of a composition directly to the connective tissue at an aneurysm through the surgical access to stabilize the tissue,
wherein the composition has a pH between about 4 and about 9, the connective tissue comprises elastin and the composition comprises a compound and a delivery vehicle,
wherein the compound is a phenolic compound having a plurality of phenolic groups that is in an effective concentration to crosslink the elastin in the connective tissue to effectively stabilize the connective tissue.
2. The method of claim 1 wherein the compound has a hydrophobic region and a plurality of functional groups capable of hydrogen bonding.
3. The method of claim 1 wherein the compound is a flavonoid or a flavonoid derivative, a flavolignan or a flavolignan derivative, a phenolic rhizome or a phenolic rhizome derivative, a flavan-3-ol or a flavan-3-ol derivative, a tannin or a tannin derivative, an ellagic acid or an ellagic acid derivative, a procyanidin or a procyanidin derivative, a combination thereof, or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 wherein the compound is anthocyanins, quercetin, (+)-catechin, (−)-epicatechin, tannic acid, pentagalloylglucose, nobotanin, epigallocatechin gallate, gallotannins, a combination thereof, or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 wherein the compound is an extract of olive oil, cocoa bean, Camellia, licorice, sea whip, aloe vera, chamomile, a derivative thereof or a combination thereof.
6. The method of claim 1 further comprising a step of applying a composition comprising glutaraldehyde to the connective tissue of the blood vessel at the aneurysm wherein the step can be performed sequentially, simultaneously, or in a combination thereof with the step of applying a composition comprising phenolic compound.
7. The method of claim 1 wherein the composition further comprises gallic acid scavenger, a lipid lowering medication, an anti-bacterial agent, or an anti-fungal agent.
8. A composition for stabilizing elastin containing connective tissue in a living subject comprising a compound and a delivery vehicle suitable to deliver the composition directly into the living subject,
wherein the compound is at an effective concentration and crosslinks elastin in the connective tissue in vivo to stabilize the connective tissue and the composition has a pH between about 4 and about 9,
wherein the composition is substantially free of unbound gallic acid and the compound is a phenolic compound having a plurality of phenolic groups, and
wherein the delivery vehicle is biodegradable.
9. The composition of claim 8 wherein the connective tissue is within a blood vessel.
10. The composition of claim 8 wherein the compound comprises pentagalloylglucose.
11. The composition of claim 8 wherein the compound has a hydrophobic region and a plurality of functional groups capable of hydrogen bonding.
12. The composition of claim 8 wherein the compound is a flavonoid or a flavonoid derivative, a flavolignan or a flavolignan derivative, a phenolic rhizome or a phenolic rhizome derivative, a flavan-3-ol or a flavan-3-ol derivative, a tannin or a tannin derivative, an ellagic acid or an ellagic acid derivative, a procyanidin or a procyanidin derivative, a combination thereof, or a pharmaceutically acceptable salt thereof.
13. The composition of claim 8 wherein the compound is anthocyanins, quercetin, (+)-catechin, (−)-epicatechin, tannic acid, pentagalloylglucose, nobotanin, epigallocatechin gallate, gallotannins, a combination thereof, or a pharmaceutically acceptable salt thereof.
14. The composition of claim 8 wherein the compound is an extract of olive oil, cocoa bean, Camellia, licorice, sea whip, aloe vera, chamomile, a derivative thereof or a combination thereof.
15. The composition of claim 8 further comprising glutaraldehyde.
16. The composition of claim 8 further comprises a gallic acid scavenger, a lipid lowering medication, an anti-bacterial agent, or an anti-fungal agent.
17. The method of claim 1 wherein the drug delivery vehicle comprises a sustained release drug delivery vehicle, a hydrogel, a perivascular drug delivery vehicle, an endovascular drug delivery vehicle, a stent or a combination thereof.
18. The composition of claim 8 , wherein the drug delivery vehicle comprises a sustained release drug delivery vehicle, a hydrogel, a perivascular drug delivery vehicle, an endovascular drug delivery vehicle, a stent or a combination thereof.
19. A method for stabilizing connective tissue in a living subject, the method comprising applying an effective amount of a composition directly to the connective tissue of a blood vessel at an aneurysm in vivo to stabilize the tissue, wherein the composition has a pH between about 4 and about 9, the connective tissue comprises elastin and the composition comprises glutaraldehyde, an elastin stabilization compound and a delivery vehicle, wherein the elastin stabilization compound interacts with the elastin in the connective tissue to stabilize the connective tissue.
20. The method of claim 1 wherein the composition is applied through perivascular or endovascular patches, vascular graft, stent or a combination thereof.
21. The composition of claim 8 wherein the phenolic compound is tannic acid or an analog of tannic acid, pentagalloylglucose or an analog of pentagalloylglucose, a combination thereof, or a pharmaceutically acceptable salt thereof.